SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

<p>Funding to support clinical advancement of SAB-142, a potential disease-modifying treatment Financing led by RA Capital Management, with participation from BVF Partners, Sessa Capital, Commodore Capital, RTW Investments, Marshall Wace, and the JDRF T1D Fund SIOUX FALLS, S.D., Oct. 02, 2023 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/sab-biotherapeutics-announces-private-placement-of-up-to-130-million-to-advance-development-of-lead-drug-candidate-for-type-1-diabetes/">SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>